Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

949
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
949
Depressants01:28

Depressants

339
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
339
Drug Therapy01:28

Drug Therapy

220
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
220
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

727
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
727
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

715
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
715
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

452
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
452

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta-Regression Study.

Alcohol, clinical & experimental research·2026
Same author

Glutamate- and GABA-targeted drugs for Cc-occurring bipolar and alcohol use disorders: a randomized, double-blind, placebo-controlled, crossover study of N-acetylcysteine, gabapentin, and placebo.

Translational psychiatry·2026
Same author

Aberrant cortico-striato-limbic functional connectivity to alcohol cues in co-occurring bipolar disorder and alcohol use disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Participant Demographic and Baseline Drinking Factors Can Predict Alcohol Use Disorder Pharmacotherapy Clinical Trial Completion and Drinking Outcomes.

Alcohol, clinical & experimental research·2026
Same author

Reductions in World Health Organization Risk Drinking Levels as a Primary Efficacy End Point for Alcohol Clinical Trials: A Review.

JAMA psychiatry·2025
Same author

New Reduced Drinking Goals in Alcohol Pharmacotherapy Trials-A Novel Public-Private Effort and FDA Approval Process.

JAMA psychiatry·2025

Related Experiment Video

Updated: Jan 2, 2026

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K

Medications for Treating Alcoholism.

Raymond F Anton1

  • 1Raymond F. Anton, M.D., is professor of psychiatry and director of alcohol medication studies at the Medical University of South Carolina, Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Charleston, South Carolina.

Alcohol Health and Research World
|December 5, 2019
PubMed
Summary
This summary is machine-generated.

Medications are being studied to treat alcoholism, including withdrawal symptoms and co-occurring mental health conditions. These drugs may also supplement behavioral therapies for better outcomes.

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.4K

Related Experiment Videos

Last Updated: Jan 2, 2026

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.4K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Addiction Medicine

Background:

  • Alcoholism presents significant public health challenges.
  • Effective treatment strategies for alcohol use disorder are in demand.
  • Current treatments include psychosocial interventions and support groups.

Purpose of the Study:

  • To evaluate the role of pharmacological interventions in alcoholism treatment.
  • To explore medications for managing alcohol withdrawal symptoms.
  • To assess medications for co-occurring psychiatric disorders in alcoholism patients.

Main Methods:

  • Review of current research on alcoholism medications.
  • Analysis of medication efficacy for withdrawal management.
  • Examination of pharmacotherapy for comorbid psychiatric conditions.

Main Results:

  • Medications show potential in managing alcohol withdrawal.
  • Pharmacological agents may help treat co-occurring mental health issues.
  • Medications can serve as an adjunct to psychosocial alcoholism treatment.

Conclusions:

  • Pharmacotherapy is a developing area in alcoholism treatment.
  • Medications offer a multifaceted approach to managing alcohol use disorder.
  • Further research is needed to optimize medication-assisted treatment for alcoholism.